By spotlighting the importance of IL6R and MYC inhibition, our research proposes a new therapeutic approach to combat Imatinib-resistant CML, paving the way for novel interventions and potentially improving treatment efficacy for patients. This evidence concerns the gene IL6R and chronic myelogenous leukemia, BCR-ABL1 positive.